Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
Axios Vitals on MSN1d
PBMs made more than $7B marking up specialty generics: FTCThe three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback